Woodline Partners’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Woodline Partners’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,004,705	Closed	-$33.5M	–	1028
2024 Q3	$33.5M	Buy	1,004,705 +940,267	+1,459%	+$32.4M	0.28%	113
2024 Q2	$1.74M	Sell	64,438 -16,482	-20%	-$325K	0.02%	432
2024 Q1	$1.75M	Buy	+80,920	New	+$1.76M	0.02%	432
2023 Q4	–	Sell	-81,279	Closed	-$452K	–	729
2023 Q3	$452K	Sell	81,279 -32,055	-28%	-$206K	0.01%	506
2023 Q2	$832K	Sell	113,334 -1,235	-1%	-$9.35K	0.01%	502
2023 Q1	$459K	Buy	+114,569	New	+$559K	0.01%	532

Woodline Partners's LBPH Position: Q4 2024 in Review

Woodline Partners sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 1,004,705 shares — an estimated $33.5M sold.

Woodline Partners first reported a position in LBPH in Q1 2023 and held it in 6 quarters. The position peaked at $33.5M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

Woodline Partners reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Woodline Partners sold 1,004,705 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $33.5M.
Woodline Partners first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Woodline Partners's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $33.5M in Q3 2024.
0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.